As discussed above, a great deal of recent interest involves conjugating monoclonal antibodies to either a cytotoxic agent, examples include brentuximab vedotin (anti-CD30-MMAE [monomethyl auristatin E]) for anaplastic large cell and Hodgkin lymphoma, trastuzumab emtansine (anti-HER2-DM1) for breast cancer, and glembatumumab vedotin (anti-GPNMB-MMAE) for breast cancer [21,26,27]. The gene discussed is ERBB2; the disease is breast cancer.